Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [517]
News [1431]
Articles [66]
Editorials [2]
Conferences [72]
elearning [5]
Trial of new ‘resistance-busting’ skin cancer drug begins as first patient receives treatment
Trial of new ‘resistance-busting’ skin cancer drug begins as first patient receives treatment
The anti-CTLA-4 antibody ipilimumab targets regulatory T cells in melanoma patients
The anti-CTLA-4 antibody ipilimumab targets regulatory T cells in melanoma patients
Results demonstrate clinical value of OCT in basal cell carcinoma diagnosis
Results demonstrate clinical value of OCT in basal cell carcinoma diagnosis
Mouse models show tailored immunotherapy to be effective
Mouse models show tailored immunotherapy to be effective
Scientists decipher key steps in cancer development to improve treatment
Scientists decipher key steps in cancer development to improve treatment
AACR 2015: Phase II trial of ipilimumab-nivolumab combo shows promise in advanced melanoma
AACR 2015: Phase II trial of ipilimumab-nivolumab combo shows promise in advanced melanoma
AACR 2015: Combining two investigational immunotherapy drugs safe, with early signs of effectiveness
AACR 2015: Combining two investigational immunotherapy drugs safe, with early signs of effectiveness
AARC 2015: Combining Chk1 inhibition with standard dose gemcitabine may be safe and effective
AARC 2015: Combining Chk1 inhibition with standard dose gemcitabine may be safe and effective
AACR 2015: New immunotherapy yields long-lasting responses in some patients with advanced melanoma
AACR 2015: New immunotherapy yields long-lasting responses in some patients with advanced melanoma
AACR 2015: Pembrolizumab is better than ipilimumab for advanced melanoma in phase III trial
AACR 2015: Pembrolizumab is better than ipilimumab for advanced melanoma in phase III trial

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation